05
Feb
2008
Posted in I - Series D, Q - 1Q08, R - INTERNATIONAL, X - Asthma, X - Biomarker, X - Crohn's, X - Schizophrenia
Genizon Biosciences (Canada) is a therapeutic target and biomarker development stage company focused on Crohn’s disease, psoriasis, asthma and schizophrenia has closed a $31M Series D. Participants include BTF B.V.
to top of page...
get your job site at simplyhired.com
© 2007 OnBioVC web design by studioJMC powered by WordPress